Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

23 Jan 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Gastrointestinal Tumor Research and Treatment
Share to Immunodeficiency and Autoimmune Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24451411
DOI: 10.1038/leu.2014.42

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerPMID 24451411Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.Semantic proximity Read ↗

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemiaSemantic proximity Read ↗

Understanding and managing ultra high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.